Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경효 | * |
dc.date.accessioned | 2018-04-25T08:13:19Z | - |
dc.date.available | 2018-04-25T08:13:19Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 0264-410X | * |
dc.identifier.issn | 1873-2518 | * |
dc.identifier.other | OAK-22203 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/242454 | - |
dc.description.abstract | Background: This study was performed with the aim of determining the long-term immunogenicity of an inactivated, Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC) and an inactivated, mouse brain-derived JE vaccine (JE-MB) after the 1st booster dose at 2 years of age, as well as the safety and immunogenicity of the 2nd booster dose of JE-VC at 6 years of age, in children primed and given a 1st booster dose of either JE-VC or JE-MB. Method: In this multicenter, open-label clinical trial, the study population consisted of healthy Korean children (aged 6 years) who participated in the previous JE vaccine trial. All subjects were subcutaneously vaccinated once for the booster immunization with Boryung Cell Culture Japanese Encephalitis Vaccine (R) (JE-VC). Result: Approximately 4 years after the 1st booster dose of JE-VC, the seroprotection rate (SPR) and geometric mean titer (GMT) of the neutralizing antibody were 100% and 1113.8, respectively. In children primed and given a 1st booster dose of JE-MB, the SPR and GMT were 88.5% and 56.3, respectively. After the 2nd booster dose of JE-VC, all participants primed and given a 1st booster dose of either JE-MB or JE-VC were seroprotective against JE virus. The GMT of the neutralizing antibody was higher in children primed and given a 1st booster dose of JE-VC (8144.1) than in those primed and given a 1st booster dose of JE-MB (942.5) after the vaccination (p < 0.001). In addition, the 2nd booster dose of JE-VC showed a good safety profile with no serious vaccine-related adverse events. Conclusion: The 1st booster dose of JE-VC and JE-MB showed long-term immunogenicity of at least 4 years, and the 2nd booster dose of JE-VC showed a good safety and immunogenicity profile in children primed and given a 1st booster dose of either JE-VC or JE-MB. (C) 2018 Elsevier Ltd. All rights reserved. | * |
dc.language | English | * |
dc.publisher | ELSEVIER SCI LTD | * |
dc.subject | Japanese encephalitis | * |
dc.subject | Vaccine | * |
dc.subject | Vero cells | * |
dc.subject | Clinical trial | * |
dc.subject | Children | * |
dc.title | Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine | * |
dc.type | Article | * |
dc.relation.issue | 11 | * |
dc.relation.volume | 36 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1398 | * |
dc.relation.lastpage | 1404 | * |
dc.relation.journaltitle | VACCINE | * |
dc.identifier.doi | 10.1015/j.vaccine.2018.01.075 | * |
dc.identifier.wosid | WOS:000427212900011 | * |
dc.identifier.scopusid | 2-s2.0-85041510649 | * |
dc.author.google | Yun, Ki Wook | * |
dc.author.google | Lee, Hoan Jong | * |
dc.author.google | Park, Ji Young | * |
dc.author.google | Cho, Hye-Kyung | * |
dc.author.google | Kim, Yae-Jean | * |
dc.author.google | Kim, Kyung-Hyo | * |
dc.author.google | Kim, Nam Hee | * |
dc.author.google | Hong, Young Jin | * |
dc.author.google | Kim, Dong Ho | * |
dc.author.google | Kim, Hwang Min | * |
dc.author.google | Cha, Sung-Ho | * |
dc.contributor.scopusid | 김경효(35448653000) | * |
dc.date.modifydate | 20240301081003 | * |